Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

Pfizer Inc. (NYSE:PFE) is among the 13 Most Undervalued S&P 500 Stocks to Invest In. On February 27, 2026, Pfizer Inc.

USA: A recent systematic review and meta-analysis published in Diabetes Research and Clinical Practice has unveiled compelling evidence that type 1 diabetes may be a significant and ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Ten years ago, a discussion in Milan set a demanding project in motion. In a meeting between a biologist and a urologist, one ...

Colorado football coach Deion Sanders was diagnosed with an aggressive form of bladder cancer earlier this year, had surgery to remove the organ and is now considered cured by his doctors, the Pro ...

Data from the IMvigor011 phase 3 study shows that adjuvant atezolizumab (Tecentriq) significantly boosts the reduction and clearance of circulating tumor DNA (ctDNA). Presented at ...

SAN FRANCISCO -- Despite a growing emphasis on quality-of-life (QoL) endpoints and patient-reported outcomes in cancer trials ...